The winners of the 7th Annual Thermo Scientific Tandem Mass Tag (TMT) Research Awards 2021 were announced on June 8th 2021 at the "Shaping the Future of LC-MS in Life Science Together" virtual innovation summit. Eligible applicants had submitted proposals describing how they will use Thermo Scientific tandem mass tag (including amine-, sulfhydryl-, or carbonyl-reactive) labeling reagents and Thermo Scientific mass spectrometry (MS) reagents in their research. A panel of judges from Thermo Fisher Scientific and Proteome Sciences, LLC selected the winners based on innovation and the potential impact of their work in proteomics. The two award winners selected will be provided up to $11,000 worth of Thermo Scientific MS reagents, free for use in their doctoral or post-doctoral research.
2021 Award Recipients
Recipient 1: $11,000
Owen Hovey is a Ph.D. student in the Lab of Dr. Shawn Li at the University of Western Ontario in London, Canada. His work focuses on the resistance of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) to tyrosine kinase inhibitors. Using a method developed by the Li lab for the enrichment of phosphotyrosine, Owen's work includes monitoring changes in phosphotyrosine signaling using mass spectrometry.
Recipient 2: $11,000
Xi Zhang is a post-doctoral fellow in Dr. Palmer Taylor's lab at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences. She is interested in deciphering the chemical nature of life, the dynamic 3D arrangement of proteins and associates by proteomics. Xi started in structural biology with membrane protein complexes research using top-down MALDI-TOF MS and crystallography in graduate school and developed structural proteomics tools for neurotransmitter receptors GPCRs and ion channels as a post-doc at Massachusetts General Hospital and Scripps Research. Recently Xi developed light-gated 3D proximity proteomics to bridge imaging with proteomic readout, and TMT Click-Phos is one way to read life’s 3D architecture with quantitative phosphoproteomics.
Learn more about past award recipients
Gold level recipient: $10,000
Suzan Stelloo, Radboud Institute of Molecular Life Sciences, The Netherlands
Dr Stelloo works in the lab of Professor Michiel Vermeulen at the Radboud Institute for Molecular Life Sciences (RIMLS) in Nijmegen, The Netherlands. The Vermeulen lab combines quantitative proteomics and genomics technologies to study the molecular signaling pathways that drive stem cell differentiation in various models (e.g., intestinal organoids and gastruloids). Suzan is currently setting up high-throughput single cell proteomics to capture protein expression changes during embryonic development.
Silver level recipient: $7,500
Samuel David Whedon, Brigham & Women's Hospital, Boston, USA
Sam is a postdoctoral fellow with Prof. Phil Cole at Brigham and Women's Hospital and Harvard Medical School. The Cole Lab focuses on protein regulation by post-translational modification, and Sam is working on regulation of chromatin by post-translational modification of the histones. Sam has a background in developing chemical methods for probing enzymatic removal of post-translational modifications. He is currently investigating new proteomic methods for characterizing the epigenomic changes accompanying healthy and pathological cell fate transitions.
Bronze level recipient: $5,000
Kevin Klann, Goethe Universität Frankfurt, Germany
Kevin is currently a PhD student in the lab of Christian Münch at the Institute of Biochemistry at the Goethe University in Frankfurt. His research focuses on the systems biology of proteome dynamics. For comprehensively measuring protein dynamics, he and the lab recently developed multiplexed enhanced protein dynamic profiling (mePROD), enabling the deep measurement of transient changes in protein synthesis. Using this new technology combined with degradation and post-translational modification profiling by mass spectrometry, his research strives to dissect the changes in protein networks upon perturbation of protein homeostasis.
Gold level recipient: $10,000
Amirata Saei Dibavar, Karolinska Institute, Stockholm, Sweden
Amir is currently a postdoc with Prof. Roman Zubarev at the Karolinska Institute in Stockholm, Sweden. He holds a doctorate in pharmacy and a Ph.D. in Medical Science. His research relates to the development of novel technologies for deconvolution of drug/biomolecule targets and mechanisms. Examples include the ProTargetMiner approach for drug target deconvolution, Proteome Integral Stability Alteration (PISA) assay for high-throughput thermal profiling, and System-wide Identification of Enzyme Substrates by Thermal Analysis (SIESTA). He is currently working on expanding ProTargetMiner applications and extending SIESTA for discovery of protein substrates for kinases and other disease-relevant enzyme systems.
Silver level recipient: $7500
Anna Andrejeva, University of Cambridge, Cambridge, UK
Dr. Andrejeva is a postdoctoral researcher at the Cambridge Centre for Proteomics directed by Prof. Kathryn Lilley, University of Cambridge. The group has been on the forefront of method development and established protocols for proteome-wide subcellular localisation (hyper LOPIT and LOPIT-DC) and recently a highly efficient unbiased method for quantitative RNA binding proteome identification (OOPS). Anna completed her PhD in Physical Chemistry and now applies mass spectrometry to biological challenges. She is engaged in the research of post-translational modification dynamics utilising bottom-up proteomics, especially related to subcellular localisation as well as their effect in the RNA-binding proteome, aiming to understand their impact in protein interactions and location.
Bronze level recipient: $5000
Paula Díez, Leiden University Medical Center, Leiden, The Netherlands
Dr. Díez is a postdoctoral researcher in the Department of Immunohematology and Blood Transfusion at Leiden University Medical Center (The Netherlands). She works in the Immune Monitoring Group (headed by Prof. Jacques JM van Dongen) developing highly standardized approaches for the microproteomics profiling of small immune populations. Specifically, she is focused on characterizing the human monocyte-macrophage maturation pathway (from bone marrow to tissues) applying different -omics strategies. Additionally, she is interested in the evaluation of lysosomal protease contents of phagocytic cells to define protein digestion patterns.
David-Paul Minde, University of Cambridge, Cambridge, UK
Dr. Minde works as postdoc in the Cambridge Centre for Proteomics with Prof. Kathryn Lilley in the Department of Biochemistry. His research explores protein dynamics using a variety of techniques. During his PhD on cancer-related Wnt signaling scaffolds, he developed a fast proteolysis assay (FASTpp) to determine protein stability and validated a 2000 residue large predicted disordered region in APC in vitro. Subsequent in singulo optical tweezers studies contributed to a paradigm shift in understanding possible cellular roles of Hsp70 chaperone systems. His current work focuses on in vivo dynamics of membrane proteins in the bacterial cell envelope specifically under poisoning conditions as part of the BBSRC-funded DETOX consortium.
Sandipan Ray, Francis Crick Institute and University College London, London, UK
Dr. Ray is a postdoctoral research associate at the UCL Institute of Neurology and a visiting scientist at The Francis Crick Institute, UK. He is working in the Biological Clocks and Sleep Group headed by Prof. Akhilesh B. Reddy. He has substantial expertise in cutting-edge proteomics technologies and big-data analysis skills with a very solid record of scientific publications in reputed journals. His current research interests are to understand the cross-talks among circadian clocks, sleep-wake cycles, and diverse signaling networks using systems-level approaches. By combining multiplexed quantitative proteomics and Thermal Proteome Profiling (TPP) he is investigating mechanisms of action of circadian period altering drugs in mammalian cells. This is critical in clearly defining molecular targets in order to modulate daily rhythms for therapeutic benefit (e.g. in shift work disorder, jet lag and sleep disorders).
Sarah Peck, Indiana University School of Medicine, Indianapolis, IN
Sarah is a graduate student in the lab of Amber Mosley in the Department of Biochemistry and Molecular Biology at Indiana University School of Medicine. The Mosley lab utilizes both proteomic and genomic approaches to study the regulation of transcription by RNA polymerase II in Saccharomyces cerevisiae. Sarah is currently developing a quantitative proteomics approach that couples an adapted cellular thermal shift assay to high resolution mass spectrometry to profile the thermal stability of proteins with missense mutations. This application provides a high throughput method to characterize the impacts of disease-associated missense mutations in proteins on the global proteome.
Edward Emmott, Northeastern University, Boston, MA
Dr Emmott is working in the quantitative biology group headed by Dr Nikolai Slavov at Northeastern University. The group currently studies ribosome heterogeneity and the refinement of single cell mass spectrometry methods (SCoPE-MS). Ed has a background in applying mass spectrometry-based quantitative proteomics to the study of virus-host interactions. His current research covers the interaction between the immune system and ribosomes, as well as helping develop SCoPE-MS for the investigation of post-translational modifications. He is also an ASAPbio and eLife ambassador, supporting the use of preprints in the life sciences, and initiatives to aid data reproducibility and reuse.
Roman Fischer, University of Oxford, Oxford, UK
Dr. Fischer leads the Discovery Proteomics Facility and is a principal investigator at the University of Oxford, UK. His lab focusses on proteomic strategies to access the deep proteome from minimal sample materials, such as cells harvested by laser-capture-microdissection. Employing a series of recently published techniques (GASP, CHOPIN) they aim at not only comprehensive proteome-, but also proteome sequence coverage to detect protein isoforms and PTMs in the context of tumor biology and drug target.
Kathryn Lilley, University of Cambridge, Cambridge, UK
Dr. Lilley is a research group leader in the Department of Biochemistry, University of Cambridge, UK. She is also the Director, Cambridge Centre for Proteomics and Head of Cambridge Systems Biology Centre. She has been at the forefront of technology development enabling mapping of the spatial proteome. Her current work investigates the implications of where transcripts are translated upon the spatial proteome and protein structure and how this process is controlled.
Kilian Huber, University of Oxford, Oxford, UK
Dr. Huber is a Principal Investigator at the Structural Genomics Consortium and Target Discovery Institute at the Nuffield Department of Clinical Medicine. His research laboratory uses a combination of chemistry and biology to develop small molecule tool compounds to explore protein function and probe cellular signaling networks related to human disease research. A second key area of interest is the development of chemical biology approaches to investigate the mechanism of action of drugs and other pharmacologically active compounds to identify future novel therapeutic targets.
Ashok Reddy, Oregon Health & Sciences University, Portland, OR
Dr. Ashok Reddy is the associate director of the Oregon Health & Sciences University Proteomics Shared Resource, and is responsible for managing proteomics projects across the entire university. He has 15 years of experience conducting cancer research and proteomics/biomarker discovery studies in human body fluids. He has managed these proteomics projects from conception to discovery as demonstrated by the discovery of candidate biomarkers of infection for pre-term birth, preeclampsia, and neonatal sepsis. His research interests are in discovery and validation of disease biomarkers in body fluids, tissues and exosomes.
Noah Dephoure, Weill Cornell Medical College,
New York, NY
Dr. Dephoure is an Assistant Professor at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College. His lab develops and refines proteomic tools and uses them to study signaling events that underlie basic cellular biology and human disease research. A long-term goal of the lab is to understand the complex roles of posttranslational protein modifications (PTMs) in cellular growth and proliferation. By combining multiplexed quantitative and temporal analysis of PTMs with novel methods for studying changes in protein interactions and subcellular localization, they are decoding the mechanisms by which these simple chemical changes impact oncogenesis and tumor progression.
Domitille Schvartz, University of Geneva, Geneva, Switzerland
Dr. Schvartz is working in the Translational Biomarker Group headed by Pr. Jean-Charles Sanchez at the University of Geneva. The group has conducted studies over the years for the discovery of diagnostic and prognostic biomarkers of brain injuries using proteomic approaches on body fluids. She has applied many “omics” approaches to her own research projects, mainly on type 2 diabetes. She is also the chair of a worldwide initiative of the Human Proteome Organization, gathering researchers in the field of diabetes and proteomics. She is now involved in a project aimed at discovering early biomarkers of drug-induced liver injury (DILI) by quantitative “omics”.
Sina Ghaemmaghami, University of Rochester, Rochester, NY
Sina Ghaemmaghami is an assistant professor of biology at the University of Rochester. His research focuses on understanding the mechanisms of cellular protein folding and degradation with a special focus on neurodegenerative disorders. He has authored more than 30 publications in journals such as Science, Nature, and PNAS. His laboratory has developed a number of commonly used proteomic methodologies for global analyses of cellular protein homeostasis.
Matthias Trost, University of Dundee, Scotland
His lab focuses on using proteomics to understand cell signaling via phosphorylation and ubiquitylation in vesicle trafficking in macrophages. They use their expertise in this area to characterize molecular mechanisms in Parkinson’s disease. Recently, they started developing mass spectrometry tools for identification of potential drug targets and drug discovery.
Jun Qu, SUNY, Buffalo, NY
His lab develops and applies LC/MS-based strategies for research in the fields of proteomics and pharmaceutical analysis, involving high-resolution and large-scale expression profiling of pathological proteomes (e.g., for cardiovascular diseases, colon cancer, and infectious diseases) for the discovery of disease/therapeutic biomarkers; identification, localization, and quantification of post-translational modifications in complex proteomes; and targeted quantification of regulatory marker proteins for research study.
Jon Reed, Roskamp Institute, Sarasota, FL
His MS lab uses integrative -omic approaches (proteomics, lipidomics, metabolomics) as well as DMPK analyses to elucidate the underlying mechanisms of several neurodegenerative diseases, and to facilitate the development of therapeutic approaches. The use of stable isotope tagging such as the TMT reagents is integral to day-to-day operations, owing to the increases in throughput and assay standardization observed relative to other techniques.
Thermo Scientific Tandem Mass Tag Research Grant Program Official Rules
NO PURCHASE NECESSARY TO ENTER OR WIN
1. HOW TO APPLY: The Thermo Scientific Tandem Mass Tag Research Grant Program (the “Program”) is void wherever prohibited or where registration or bonding is required, and is subject to all applicable laws. To participate in the Program, you must submit your Grant Application (Application) at www.thermofisher.com/tmtgrant. All required information on the Application form must be completed. All Applications must be submitted in the English language. The Application must be received by Sponsor between 12:01 AM US Pacific Time on September 30, 2020 and 11:59 PM US Pacific Time on February 28, 2021. By applying, you represent that you are not prohibited by employment, law, regulation, or the policies or practices of your institution or employer from participating.
2. ELIGIBILITY: The Program is open only to doctoral or post-doctoral students at academic, not-for-profit research institutions or commercial entities located in an eligible jurisdiction whose representative has submitted a completed Application. The person submitting the Application is the applicant (“Applicant”) and is entering on behalf of their employer, which will be the recipient of the grant (“Grant Recipient”). Applicant warrants that they have obtained any necessary permission to submit an Application to this Program and authorization from their employer or responsible supervisor. The Program is open only to Applicants who are new users of Thermo Scientific™ Tandem Mass Tag™ reagents or Thermo Scientific™ TMT™ reagents (the “Reagents”). Determination of eligibility is at Sponsor’s sole discretion. Affiliates, subsidiaries, advertising, promotion, and fulfillment agencies of Sponsor, and immediate family members and employees, officers and directors of Sponsor or those living in their same household, are not eligible to participate. By entering, Applicants give permission to Sponsor to contact them about its products and services, whether or not Applicant is selected to receive an award.
Healthcare Professionals located outside of Europe, the Middle East and Africa may not participate in this promotion. The term Healthcare Professionals includes clinical or non-clinical physicians (including MDs and MDs/Ph.Ds), and physician assistants, nurses, technicians, research coordinators, administrators and purchasing personnel and entities (including hospitals, rehabilitation centers, nursing facilities, home health agencies, clinics and group purchasing organizations, managed care organizations, physician group practices, medical directors for health insurance organizations, diagnostic institutions) and their employees and representatives who are involved in the actual provision of health care services.
Healthcare Professionals located in Europe, the Middle East and Africa may not participate in this promotion. The term Healthcare Professional means any individual (with a clinical or non-clinical role; whether a government official, or employee or representative of a government agency or other public or private sector organization; including but not limited to, physicians, nurses, technicians, laboratory scientists, researchers, research co-ordinators or procurement professionals) that in the course of their professional activities may directly or indirectly purchase, lease, recommend, administer, use, supply, procure or determine the purchase or lease of, or who may prescribe medical technologies or related services. The definition of Healthcare Professionals includes individuals involved in research activity, not just those directly involved in the provision of healthcare services.
Government Officials located in Australia, New Zealand, Taiwan, Singapore, China, Europe, the Middle East and Africa may not participate in this promotion. Government Official shall mean: (i) Any officer or employee of a government or any department, agency or instrument of a government; (ii) Any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (iii) Any officer or employee of a company or business, university or institution owned or funded in whole or part by a government; (iv) Any officer or employee of a public international organization such as the World Bank or United Nations, the European Union or the World Health Organization; (v) Any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or (vi) Any candidate for political office.
Void in Quebec, India, and where prohibited, licensed, or restricted by federal, state, provincial, or local laws, regulations, or agency/institutional policy.
3. SELECTION: The object of the Program is to encourage new and novice users of Thermo Scientific™ TMT™ (including amine-, sulfhydryl- or carbonyl-reactive) labeling technology or who have recently started using quantitative discovery proteomic techniques. Submit the best ideas for applications of the Applicant’s experiment to show feasibility with the Reagents. In order to be considered for selection, Applicants must have the following available in connection with their proposal: biological samples and access to Thermo Scientific™ instruments that are compatible with the Thermo Scientific™ tandem mass tag labeling reagents. Applications will be judged by a panel of five R&D professionals from Sponsor and Proteome Sciences Plc based on the following criteria, each worth 25% of the total score:
- Scientific merit: Use of novel applications for discovery quantitative proteomics to achieve their goals by using tandem mass tag labeling reagents and MS reagents
- Significance of use of Thermo Scientific™ TMT™ tags and commercial MS reagents: How using tandem mass tag labeling reagents will further the research
- Approach: How clear and well developed is the proposed use of the TMT tags and MS reagents to address the questions at hand; what instrumentation is available for analysis
- Equipment: Use of Thermo Fisher Scientific mass spectrometry instruments in their application proposal
All qualifying applications will be anonymized prior to presentation to the judges. Judges’ decisions are final on all matters and shall not be subject to challenge or appeal.
4. NOTIFICATION AND GRANT RECIPIENTS’ OBLIGATIONS: The two Grant Recipients will be notified by March 31, 2021 and, if eligible, recognized at the ASMS conference in Philadelphia, PA during a Thermo Scientific sponsored event between June 6th and June10th 2021 or in case of cancelation of the live event, at an equivalent virtual event. By participating, Applicants and Grant Recipients agree to these Official Rules, the Pierce Biotechnology, Inc. Products Terms and Conditions of Sale (applied to each Grant Recipient as if the Grant Recipient had ordered the product awarded), and the determination of each Grant Recipient by Sponsor, which shall be final and binding in all respects. Applicants and Grant Recipients acknowledge and agree that they will provide the protocols they utilize in the project and any resulting data (the “Results”) to Sponsor for use by Sponsor, in its sole discretion, on websites of Sponsor and/or its affiliates or otherwise. Acceptance of the award constitutes permission to use a recipient’s name, biographical information, likeness and company information without further compensation, except where prohibited by law and as otherwise provided herein. No information regarding judging or selection will be disclosed.
5. AWARD: Two Grant Recipients will be selected to receive a product credit for Thermo Scientific tandem mass tag labeling reagents and MS reagents in the amount of $11,000 USD each (or equivalent in the local currency of the Grant Recipient) (the “Award”). Limit one Award per Grant Recipient. The Award must be used in a single purchase order. The Award must be used by no later than September 31, 2021. The number of recipients selected will be in Sponsor’s sole discretion and based on evaluation of the contents of the Application and the description of the proposed project. No financial or other compensation will be made for any other purpose, and Grant Recipient agrees to provide all other materials, personnel, laboratory space and equipment necessary, and to bear the expenses of their project. Applicants for the Grant Recipient will be attempted to be notified by email or mail. Any notification returned as undeliverable may result in disqualification. The Award is not transferable; no substitutions or cash equivalents are allowed, except at Sponsor’s sole discretion. The Applicant will be required to execute and return an Affidavit of Eligibility/Release of Liability/Assignment of Rights/Publicity Release (where legal) and the Grant Recipient will be required to execute and return an Acceptance of Grant document. Each document must be signed and returned to the Sponsor within 14 calendar days of notification attempt. If the Applicant and/or Grant Recipient fail to return these documents by the deadline, the grant will be forfeited and an alternate recipient may be determined, based on the criteria set forth above. TAXES, INCLUDING SALES, FEDERAL, STATE, AND LOCAL TAX, IF ANY, RELATED TO THE AWARD ARE THE RESPONSIBILITY OF THE GRANT RECIPIENT AND SPONSOR WILL, IF APPLICABLE, ISSUE A 1099-MISC TO THE GRANT RECIPIENT. No responsibility or liability is assumed for damages, losses or injury resulting from acceptance or use of any Award. All other expenses and costs not expressly listed above are each Grant Recipient’s sole responsibility.
6. INTELLECTUAL PROPERTY: Ownership of the pre-existing underlying intellectual property of the Grant Recipient remains the property of the Grant Recipient subject to Sponsor's rights to reprint, display, reproduce, perform, use and exhibit the Application and any Results for the purpose of administering and promoting the Program and for Sponsor's marketing and advertising purposes. By participating in the Program, each Grant Recipient grants to Sponsor a non-exclusive, worldwide, fully paid, royalty-free, perpetual, transferable license to reprint, display, reproduce, perform, use and exhibit (including the right to make derivative works of) the Application and materials, and information submitted on and in connection with the Program or use or receipt of the award, as well as materials and information provided by Sponsor for the purposes of running this Program, and the Results. Each Applicant and Grant Recipient hereby warrants that any Application and other materials and information provided by Applicant, and any Results, are original with Grant Recipient and do not violate or infringe upon the copyrights, trademarks, rights of privacy, publicity or other intellectual property, or other rights of any person or entity, and do not violate any rules or regulations. If the Application or information or materials provided by participant, and any Results, contain any material or elements that are not owned by participant and/or which are subject to the rights of third parties, Applicant represents that he or she has obtained, prior to submission of the Application and information or materials, and any Results, any and all releases and consents necessary to permit use and display of the Application, information and materials, and Results by Sponsor in the manner set forth in these Official Rules without additional compensation.
7. GENERAL RULES: In the event of a dispute regarding any Application, that Application will be deemed made by the first qualifying Applicant to submit the Application. Return of any award or award notification as undeliverable may result in disqualification and alternate determination. By participating in this Program, Applicants and Grant Recipients agree to be bound by these Official Rules and the decisions of Sponsor. Sponsor is not responsible for technical, hardware, software or telephone malfunctions of any kind; lost or unavailable network connections; or failed, incorrect, incomplete, inaccurate, garbled or delayed electronic communications caused by the user or by any of the equipment or programming associated with or utilized in this Program, or by any human error that may occur in the processing of the online Application in this Program. Sponsor reserves the right at its sole discretion to disqualify any Applicant or Grant Recipient who tampers or attempts to tamper with the Application process or the operation of the Program or website; violates the Official Rules; or acts in an unsportsmanlike or disruptive manner, or with intent to annoy, abuse, threaten or harass any other person. Any attempt by any person to deliberately undermine the legitimate operation of the Program may be a violation of criminal and civil law, and, should such an attempt be made, Sponsor reserves the right to seek damages from any such person and participant to the fullest extent permitted by law. Sponsor's failure to enforce any term of these Official Rules shall not constitute a waiver of that provision. Sponsor reserves the right, at its sole discretion, to cancel, terminate, modify or suspend the Program if it is not capable of running as planned due to circumstances including, but not limited to, infection by computer virus, tampering, unauthorized intervention, fraud, technical failures or any other problems beyond the control of Sponsor. Sponsor and each of its respective affiliates, officers, directors, agents and employees will have no liability or responsibility for any claim arising in connection with participation in this Program or any award. Each Grant Recipient assumes all liability for any injury or damage caused, or claimed to be caused, by participation in this Program or use or redemption of any award.
8. RELEASE/LIMITATIONS OF LIABILITY: YOU HEREBY HOLD SPONSOR HARMLESS FROM AND AGAINST ANY THIRD-PARTY CLAIM ARISING FROM USE OF THE PROGRAM, THE APPLICATION, OR THE RESULTS. SPONSOR AND ITS AGENTS ARE NOT RESPONSIBLE FOR LOST, LATE, DAMAGED, MISDIRECTED, ILLEGIBLE, INCOMPLETE OR MUTILATED APPLICATIONS; OR FOR ANY COMPUTER, ONLINE, TELEPHONE OR TECHNICAL MALFUNCTIONS, DELAYS OR HUMAN ERRORS THAT OCCUR IN THE PROCESSING, TRANSMISSION OR RECEIPT OF APPLICATIONS; OR FOR INACCURATE TRANSCRIPTION OF APPLICATION INFORMATION; OR FOR APPLICATIONS THAT ARE STOLEN, MISDIRECTED, GARBLED, LOST OR DELAYED BY COMPUTER TRANSMISSIONS; OR IF FOR ANY REASON THE PROGRAM IS NOT CAPABLE OF BEING CONDUCTED AS PLANNED, INCLUDING BUT NOT LIMITED TO INFECTION BY COMPUTER VIRUSES, BUGS, TAMPERING, UNAUTHORIZED INTERVENTION, FRAUD, TECHNICAL FAILURES OR OTHER CAUSES BEYOND THE CONTROL OF SPONSOR. SPONSOR RESERVES THE RIGHT AT ITS SOLE DISCRETION TO CANCEL, TERMINATE, MODIFY OR SUSPEND THE PROGRAM. SPONSOR IS NOT RESPONSIBLE FOR INCORRECT OR INACCURATE APPLICATION INFORMATION, WHETHER CAUSED BY INTERNET USERS OR BY ANY OF THE EQUIPMENT OR PROGRAMMING ASSOCIATED WITH OR UTILIZED IN THE PROGRAM, OR BY ANY TECHNICAL OR HUMAN ERROR THAT MAY OCCUR IN THE PROCESSING OF THE APPLICATIONS IN THE PROGRAM.
9. CHOICE OF LAW; VENUE: Any disputes in connection with this Program will be resolved in the appropriate courts in San Diego, California, and will be subject to the laws of California, exclusive of its conflicts of laws principles.
10. SPONSOR: The Sponsor of the Program is: Pierce Biotechnology, Inc., a subsidiary of Thermo Fisher Scientific Inc. 3747 N. Meridian Rd. P.O. Box 117 Rockford, IL 61105
Tandem Mass Tag, TMT and are trademarks of Proteome Sciences.
For Research Use Only. Not for use in diagnostic procedures.